Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-READ: Pembrolizumab De-escalation in Metastatic Urothelial Carcinoma
NCT07183319Phase 2Recruiting
- Sponsor
- University of Oklahoma
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in urothelial carcinoma (UC), sponsored by University of Oklahoma. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07183319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183319.